Wolfe Research downgraded Alnylam (ALNY) to Underperform from Peer Perform, citing “unfriendly channel dynamics coupled with inability to rebate.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALNY:
- Alnylam price target raised to $298 from $275 at Raymond James
- Alnylam price target raised to $310 from $305 at Scotiabank
- Alnylam price target raised to $384 from $366 at Canaccord
- U.S. drugmakers shifting away from Chinese supply-chain partners, WSJ says
- Alnylam price target raised to $329 from $295 at Barclays
Questions or Comments about the article? Write to editor@tipranks.com